Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  1.95 9.4% 22.70 4,889,693 16:35:09
Bid Price Offer Price High Price Low Price Open Price
22.50 23.00 22.85 20.75 20.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -16.81 -2.28 180
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:45 O 149,000 22.70 GBX

Scancell (SCLP) Latest News

More Scancell News
Scancell Investors    Scancell Takeover Rumours

Scancell (SCLP) Discussions and Chat

Scancell Forums and Chat

Date Time Title Posts
27/11/202220:09Using immunology to fight cancer.55,730
27/11/202217:11Scancell - Pot of Gold or POS?1,161
22/11/202214:00Using immunology to fight cancer.1
11/9/202210:09Question12
12/4/202206:51Professor Christian Ottensmeier-

Add a New Thread

Scancell (SCLP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Scancell trades in real-time

Scancell (SCLP) Top Chat Posts

Top Posts
Posted at 27/11/2022 08:20 by Scancell Daily Update
Scancell Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 20.75p.
Scancell Holdings Plc has a 4 week average price of 15p and a 12 week average price of 10.75p.
The 1 year high share price is 22.85p while the 1 year low share price is currently 10.60p.
There are currently 791,917,828 shares in issue and the average daily traded volume is 760,546 shares. The market capitalisation of Scancell Holdings Plc is £179,765,346.96.
Posted at 26/11/2022 09:20 by inanaco
Ivy its not me with an EGO problem .......... I actually tried to help you

done it many times ........ but your so pig headed ...


inanaco - 23 Nov 2022 - 05:38:07 - 55421 of 55665 Using immunology to fight cancer. - SCLP
my advice ....... "review" your portfolios

Ivy ...... it makes no difference to me if you don't...

but

Calculus has just sold at least 2% of its holdings .... or 16m shares without affecting the share price ... we won't know what they hold now

it stopped the share price climbing ... but fed the desire to hold Scancell

and we still don't have the big news ... as its only 1 patient

Posted at 23/11/2022 10:26 by inanaco
LOL ......... Burble clearly understands what i post .........



inanaco - 07 Jul 2021 - 07:32:39 - 41681 of 52679
the FULL TEXT .... written by Burble PHD

AB, I really don't mind and don't really care to be honest. This board should not be about infighting and one-up-man-ship and instead should be about education, research and critique of the science and business, not of each others personalities, knowledge or lack of.

If it wasn't for Inan, his research and knowledge, I probably wouldn't be here or possibly wouldn't have been here so early on in my investment journey. I first invested in SCLP back in 2011 when I was sat working at Pfizer. I sat down and googled any listed company in the UK and what they did. Then I started watching these chat threads from the sidelines. For a number of years, I have been a wall-flower, listening in from the sidelines to this board and others. Reading, understanding and researching. Inan has been incredibly informative to me and many others across the years with his research into scancell. Yes we have had our differences along the way, but I am happy to have been challenged on my posts by him and others and be presented with new data as I feel this can only strengthen my knowledge and make me go away and research further.

For me this board should be about educating people, answering questions people may have about the science in a way that is accessible to all. But also, give a factual balanced view which highlights strengths and weaknesses of the research. So often on pharma investments it's easy for many to get drawn into believing the science is infallible, that it will lead to successful therapies for patients and profits for us all as investors. But the sad truth is many pharma companies and their promising early phase drugs fail in clinical trials. Hence I have always tried to present as neutral and balanced view as possible by presenting the science behind SCLP, highlighting areas where it could fail, but also highlight areas where our platforms have strengths over and above what others in the area have to offer.

My reason for investing lies on the fact I believe SCLP have platforms which can change cancer treatment for the better, not just for one disease but for cancer as a whole. The financial gain for me as an investor, is an aside from this.

If you understand the science, you are able to make your own decisions as to where this company is going. If you understand the science you realise that SCLP is taking a different approach to others which could unlock many therapies for patients across the globe in oncology and now infectious disease. If you understand the science, you can also understand the risks involved in this area of investment/business.

Posted at 23/11/2022 09:44 by inanaco
present for you Ivy


Ivyspivey - 28 Oct 2022 - 09:44:14 - 54494 of 55449 Using immunology to fight cancer. - SCLP
Morning Tosh no doubt he is babbling on again but correct reason to filter him as he has such a negative mindset.
All I said before Wednesdays news was that a profitable revenue producing Company that has enough cash never to raise again was less risky than any pre revenue bio pharma whatever the potential.
But of course he can see into the future or pretends he can so he can never be wrong lol.
The stupid thing is we need new investors to increase the share price and he expects people to believe him.
Well we put our BTL on the market and it was bought by first viewer in excess of asking price yesterday so we have agreed a deal.
I could of course use the proceeds to buy shares here to have the same holding as Nana and if he was balanced then I may be more inclined.
But his over the top no risk all in approach actually frightens off more potential investors than attracting them so he defeats his own purpose- crass stupidity.

Posted at 22/11/2022 13:26 by inanaco
so your talking share price £2 = mcap


you better think hard about the profit and loss account ... Ruck

because total expenditure - income is what I have just used ....

not a yearly number but the whole number .... since we started

which is why lindy used 88m at the end of next year ..... the total carry ... however i don't have next years share price ... so i have to use today ... hence i use a £60m carry


your problem is you don't have a clue how accounts operate

bit like Ivy ...

Posted at 22/11/2022 07:50 by inanaco
just to put the record straight on this post .. which apparently I claimed as my own .... when i actually didn't ..... as you see from the post above our friend was actually posting on the day i made this post, I can't confirm who wrote, but strangely enough he does not mention it despite Knowlesi posting here on the 28th, i cant check his LSE account but they don't carry full history anyway because its deleted .... but why has Knowlesi not charged me with plagiarism on the 28th ??







inanaco - 20 Nov 2022 - 10:58:45 - 55288 of 55355 Using immunology to fight cancer. - SCLP
out of interest i found the 2015 AGM Post i made ( i think its mine) on the lse and copied on to here



inanaco - 28 Oct 2015 - 11:27:55 - 3571 of 55288 Using immunology to fight cancer. - SCLP
SCLP
AGM
20 Oct '15

Here's my thoughts of today's AGM - these are just my own thoughts and takeaways - please read others thoughts for a more full picture.

My takeaways - the science is incredible and has tweaked a lot of interest but this is very much a long term play - I didn't get the sense of an share price catalyst coming anytime soon.

Pros - science (as always) - trial results continue to be mind blowing. Moditope looks incredible! John chippin seems a very strong addition to the team - he spoke well and seems to have a good mix of commercial/funding and clinical experience. We are fully funded to at least this time next year.

Cons - It seems CDA negotiations haven't been as expected - while options are still being discussed according to DE, I came away with the feeling that some of the negotiations have broken off. No clear funding or commercial strategy was communicated - I came away still unsure of our plan. Our trial sizes are to small to have big pharma falling over themselves - DE alluded to this.

Interesting questions: there was a question about scib2/3 wasn't mentioned. The answer from RG was that we have to prioritise and they are still in our plans but aren't priority given our funding position.

Question around would dwindling finance affect our negotiating position. Ans from DE - non committal (as expected).

Question around how long it would take from funds being available to modi 1 being i phase I. Ans from LD - 12 months - ready to go just pending cash.

Personal thoughts post AGM: concerned, I came away less bullish for sure. The big question I had going in was an I happy to keep topping up at these levels - having attended today I would have to say no - but I will not be selling. I didn't get the sense that anything that could spur as a catalyst for the share price was on the horizon - in could be a tricky 4-5 months for the share price and i expect to see some further weakening. RG mentioned that it was hard to get senior decision makers from big pharma together for meetings - I was worried by this comment more than any other. You take the meetings you want and delay others. RG was generally subdued and quiet - his update was painfully brief and lacking anything new. DE tackled the trickier questions.

Body language: hard to gauge from RG & DE but fairly neutral. DE seemed quiet negative in his tone. LD looked almost apologetic. JC seemed confident - he spoke of the strength of the data and the confidence he had in getting scib1 onto phase 3.

In short - I am still happy to hold but this could take longer than I thought to get a a decent share price rally. Science remains amazing - LD is incredible and I wish we could give her the finances to make things happen now.

Posted at 20/11/2022 14:32 by tosh123
" inanaco - 09 Aug 2013 - 07:48:27 - 1144 of 55289 Using immunology to fight cancer. - SCLP "

So this was nearly 9 and a half years ago.... the share price was in the mid 35p range eg HALF of what it is today ,( nearly a decade later )... You were actively buying here at at these prices eg 35p and above... the price continued to fall back to 3.5p and .... YOU now have the audacity to attempt to poke fun at another poster about one of their other investments !!

You can't make this stuff up... Hence why people laugh at you.

You try to mock the very thing that YOU are more guilty of than ANYONE else on this BB.

Posted at 20/11/2022 10:58 by inanaco
out of interest i found the 2015 AGM Post i made ( i think its mine) on the lse and copied on to here



inanaco - 28 Oct 2015 - 11:27:55 - 3571 of 55288 Using immunology to fight cancer. - SCLP
SCLP
AGM
20 Oct '15

Here's my thoughts of today's AGM - these are just my own thoughts and takeaways - please read others thoughts for a more full picture.

My takeaways - the science is incredible and has tweaked a lot of interest but this is very much a long term play - I didn't get the sense of an share price catalyst coming anytime soon.

Pros - science (as always) - trial results continue to be mind blowing. Moditope looks incredible! John chippin seems a very strong addition to the team - he spoke well and seems to have a good mix of commercial/funding and clinical experience. We are fully funded to at least this time next year.

Cons - It seems CDA negotiations haven't been as expected - while options are still being discussed according to DE, I came away with the feeling that some of the negotiations have broken off. No clear funding or commercial strategy was communicated - I came away still unsure of our plan. Our trial sizes are to small to have big pharma falling over themselves - DE alluded to this.

Interesting questions: there was a question about scib2/3 wasn't mentioned. The answer from RG was that we have to prioritise and they are still in our plans but aren't priority given our funding position.

Question around would dwindling finance affect our negotiating position. Ans from DE - non committal (as expected).

Question around how long it would take from funds being available to modi 1 being i phase I. Ans from LD - 12 months - ready to go just pending cash.

Personal thoughts post AGM: concerned, I came away less bullish for sure. The big question I had going in was an I happy to keep topping up at these levels - having attended today I would have to say no - but I will not be selling. I didn't get the sense that anything that could spur as a catalyst for the share price was on the horizon - in could be a tricky 4-5 months for the share price and i expect to see some further weakening. RG mentioned that it was hard to get senior decision makers from big pharma together for meetings - I was worried by this comment more than any other. You take the meetings you want and delay others. RG was generally subdued and quiet - his update was painfully brief and lacking anything new. DE tackled the trickier questions.

Body language: hard to gauge from RG & DE but fairly neutral. DE seemed quiet negative in his tone. LD looked almost apologetic. JC seemed confident - he spoke of the strength of the data and the confidence he had in getting scib1 onto phase 3.

In short - I am still happy to hold but this could take longer than I thought to get a a decent share price rally. Science remains amazing - LD is incredible and I wish we could give her the finances to make things happen now.

Posted at 20/11/2022 07:04 by inanaco
18 months ago .......... Orph at 30p .... expectation ... £2billion No risk

Current value ... 2.57 times ""less risky"" than AZN at Mcap of 65m

AZN pays dividend at approx 3%

Facts are Facts .....


Ivyspivey - 13 Mar 2021 - 16:52:53 - 37999 of 45080 Using immunology to fight cancer. - SCLP
Well we can try.
Firstly it is profitable and generates plenty of cash so does not need to raise.
Current global leader in HC studies with U.K. Govt contract of £46m and likely another £50m announced in next few weeks.
Currently doing work with 4 of top 5 big pharma.
Has ambitions to be a $1bn Company within 12-18 months based on current outlook.
Has 4 potential disposals of non core assets again could total $1bn plus again within 6 months.
The CEO has about £20m of his own money tied up and wants to buy more.
All of the above does nit depend on any trial results as they get paid whether trial is a success or not.
I am not saying that SCLP will not increase its share price more than ORPH it could if say Covid Vax comes good and SCIB1/ Combo and Modi 1 gets successful results.
But if I was investing £300k then personally I would not risk all of it in SCLP which may 20 bag but also there is risk when I could stick say £200k in ORPH which imo has very little risk of going down and is very likely to go up at least 5 fold within 12 months and say a £100k in SCLP.
I am not criticising your choice but equally please don’t have a go at someone who chooses a different path

Posted at 19/11/2022 07:54 by ivyspivey
Hi MT,
The previous recordings were “ unofficial” so a PI recording proceedings in their phone.
You would normally get the presentation slides posted but not the accompanying audio and of course the all important Q and A session.
As you said the real benefit of attending is to gauge the feelings in the room and the discussions outside of the formal bits.
I really don’t get why if you have a big holding and can make it you would not attend as one of the very limited opportunities to actually meet and question the people that ultimately are in charge of a good part of your wealth.
However you do need an open mind and a semblance of EQ. If you have a closed mind and zero EQ ruthenium I do understand why it would be a waste of time in attending.
Most AGMs do not on their own reveal much as they are simply part of a formal process if corporate governance.
However although the recent SCLP ones have fallen into this category the 2015 one was seminal in directly impacting on the share price so being there was of real benefit to holders and potentially this years could be equally as significant but much more likely to have a polar opposite effect to the share price than 2015.

Posted at 05/11/2022 15:57 by ivyspivey
As you say Loggie an excellent week for SCLP and admit the benefits of trading are much more limited than previously as you say news can drop anytime and the recent stuff has been very positive.
Having said that we know SCLP does tend to have gaps between news so will traditionally drift down.That is why I try and take a wider view of who is buying here and trader noise as you can often get a much better feel for how the share price will move but you need to put the time in and understand it which you won’t do if you just focus on the BBs.
I always keep a core holding so if some huge news drops then I will still gain and I am not greedy so happy with either scenario.
I am with you this may have the potential to be many multiples like many AIM shares but experience tells you they never get there including being taken out much lower.
RM and Vulpes control what happens here so if an offer comes in at £1 a share then there is a fair chance they will cash in and retail will have to accept it.
It will be very difficult for anyone pharma to buy SCLP as yes they may want one platform like Moditope but they won’t want the other stuff and they don’t buy to asset strip or sell off other bits as that is not how they operate.
Modi is an interesting one as the Science is more appealing to likes of Bion Tech than traditional big pharma but data will determine outcome.
We all know the lesson from SCIB 1 and the swimmer chart and yes showed compelling results but no deal so let us just be patient.
Many anticipated good Modi results in humans based on pre clinical data but just kept their counsel or were prepared just to wait for real time data rather than claim they were the only one to foresee it.
Only a bit of sport with Nana whilst watching RL on a quiet afternoon so don’t worry.

Scancell share price data is direct from the London Stock Exchange
Your Recent History
LSE
SCLP
Scancell
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221128 06:01:58